Nuwellis Q1 2025 revenue $1.9M (+3% YoY); net loss narrows to $3.0M

Nuwellis, Inc.

2025-Q1 EPS reported -$0.69 vs consensus -$32.56 ▲ beat (+97.9%)

Revenue $1.9M (+3% YoY); consumables utilization +4%; pediatric revenue +38%.
Operating expenses down 31% to $4.1M; operating loss improved to $3.1M from $4.7M.
Net loss $3.0M ($0.69/sh) vs $3.8M ($24.11/sh) in Q1 2024.
CMS reassigned Aquadex to higher outpatient reimbursement (4x to $1,639/day) effective Jan 1, 2025.
Cash $2.6M, debt-free.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.